Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.56 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.56 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CETP | P11597 | 1/20 | 0.50 |
| ▸ | IGF2R | P11717 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butylalphaman SCHEMBL17547738 | 1.00 | MAPK1 (0.57) | MAPK1LGALS8LGALS3LGALS4L3MBTL1 | |
| Butylalphaman SCHEMBL2444936 | 1.00 | MAPK1 (0.57) | MAPK1LGALS8LGALS3LGALS4L3MBTL1 | |
| Butylalphaman SCHEMBL17547737 | 1.00 | MAPK1 (0.57) | MAPK1LGALS8LGALS3LGALS4L3MBTL1 | |
| Butylalphaman SCHEMBL15281426 | 1.00 | MAPK1 (0.57) | MAPK1LGALS8LGALS3LGALS4L3MBTL1 | |
| Butylalphaman SCHEMBL14210603 | 1.00 | MAPK1 (0.57) | MAPK1LGALS8LGALS3LGALS4L3MBTL1 | |
| Butylalphaman SCHEMBL6130531 | 1.00 | MAPK1 (0.57) | MAPK1LGALS8LGALS3LGALS4L3MBTL1 | |
| Butylalphaman SCHEMBL17547765 | 1.00 | MAPK1 (0.57) | MAPK1LGALS8LGALS3LGALS4L3MBTL1 | |
| Butylalphaman SCHEMBL2444892 | 1.00 | MAPK1 (0.57) | MAPK1LGALS8LGALS3LGALS4L3MBTL1 | |
| Butylalphaman SCHEMBL21518298 | 1.00 | MAPK1 (0.57) | MAPK1LGALS8LGALS3LGALS4L3MBTL1 | |
| Butylalphaman SCHEMBL17300154 | 1.00 | MAPK1 (0.57) | MAPK1LGALS8LGALS3LGALS4L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846686-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2559735-A1 | THERMOPLASTIC POLYMER COMPOSITION AND PROCESSING STABILISER | Sumitomo Chemical Company Limited (JP) | 2013-02-20 | — | — | EP | disclosed |
| US-20130032756-A1 | THERMOPLASTIC POLYMER COMPOSITION AND PROCESSING STABILISER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-02-07 | — | — | US | disclosed |
| US-8017673-B2 | Polymer stabilizer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-09-13 | — | — | US | disclosed |
| US-20100179253-A1 | POLYMER STABILIZER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-07-15 | — | — | US | disclosed |
| EP-2206740-A2 | Polymer stabilizer | Sumitomo Chemical Company, Limited (JP) | 2010-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179253-A1 | POLYMER STABILIZER | CNOT1, PARP1, FKBP1B | MAPK1 3071/4885LGALS8 3781/4885LGALS3 3189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.